452 Pill: blue, capsule/oblong, 24mm
The pill with imprint 452 (Blue, Capsule/Oblong, 24mm) has been identified as Mesalamine Extended-Release 0.375 g and is used for Ulcerative Colitis, Maintenance, Ulcerative Colitis, Active, Crohn's Disease, Maintenance, Ulcerative Proctitis, and Ulcerative Colitis. It belongs to the drug class 5-aminosalicylates and is not a controlled substance.
Images for 452
Mesalamine Extended-Release
- Imprint
- 452
- Strength
- 0.375 g
- Color
- Blue
- Size
- 24.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- 5-aminosalicylates
- Pregnancy Category
- B - No proven risk in humans - excluding Asacol and Asacol HD, C - Risk cannot be ruled out - Asacol and Asacol HD
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Zydus Pharmaceuticals (USA) Inc.
- Manufacturer
- Cadila Healthcare Limited
- National Drug Code (NDC)
- 68382-0452
- Inactive Ingredients
-
ethylcellulose (10 mPa.s),
hypromellose 2910 (5 mPa.s),
methacrylic acid - methyl methacrylate copolymer (1:1),
talc,
triethyl citrate,
FD&C Blue No. 1,
gelatin,
water,
sodium lauryl sulfate,
titanium dioxide,
ferrosoferric oxide,
potassium hydroxide,
propylene glycol,
shellac,
sucrose,
corn starch
Note: Inactive ingredients may vary.
Related images for "452"
More about mesalamine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (426)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: 5-aminosalicylates
- Breastfeeding
Patient resources
- Mesalamine drug information
- Mesalamine rectal
- Mesalamine (Oral) (Advanced Reading)
- Mesalamine (Rectal) (Advanced Reading)
Other brands
Lialda, Pentasa, Apriso, Asacol HD, ... +4 more
Professional resources
- Mesalamine monograph
- Mesalamine (FDA)
- Mesalamine Capsules (FDA)
- Mesalamine Controlled-Release Capsules (FDA)
- Mesalamine Delayed Release Tablets (FDA)
Other brands
Lialda, Pentasa, Asacol, Apriso, ... +5 more
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.